Text Size

Parkinson's Disease Evaluated by PET and the Effect of Memantine

This study has been completed.
Sponsor:
Collaborator:
Lundbeck Foundation
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00375778
First received: September 12, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted
  Purpose

Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).

Background: Disturbances in brain metabolism is thought to contribute to degeneration of neurons in brain of PD patients. Production of toxic oxygen radicals and presence of too much excitatory neurotransmitter (glutamate) due to over activity is involved. These factors can theoretically be alleviated by memantine.

Hypothesis: Memantine decreases metabolism in areas in PD brain known to be over-active. Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET.


Condition Intervention
Parkinson's Disease
 Drug: memantine (drug)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Aarhus:

Estimated Enrollment: 12
Study Start Date: April 2005
Estimated Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   50 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Parkinson's Disease (British Brain Bank Criteria)
  • Age 50-70y

Exclusion Criteria:

  • Tobacco use
  • Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)
  • Metal implants contraindicating MR scan
  • Drug use affecting the central nervous system
  • Psychiatric disorders
  • Head trauma or any disorders of the head, skull or brain
  • Drug addiction or use of any kind of illegal substance affecting the central nervous system
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375778

Locations
Denmark
PET center, Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Lundbeck Foundation
Investigators
Principal Investigator: Karen Ostergaard, MD, Ph.D Department of Neurology , Aarhus University Hospital, Denmark
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00375778     History of Changes
Other Study ID Numbers: 2004-004139-74
Study First Received: September 12, 2006
Last Updated: September 12, 2006
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by University of Aarhus:
Parkinson's Disease
Positron Emission Tomography
Memantine
 NMDA antagonists
Cerebral Blood Flow
Cerebral Metabolic Rate of Oxygen

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Memantine
Dopamine Agents
 Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 18, 2013